# Zomedica Corp. (ZOM)

Source: https://www.quantisnow.com/company/ZOM
Generated: 2026-11-20T05:02:52.555Z

- Ticker: ZOM
- Exchange: AMEX
- Sector: Health Care
- Industry: Pharmaceuticals and Biotechnology
- IPO year: 2017
- Website: zomedica.com

## About

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

## Latest ZOM news and filings

- 2026-02-24 12:05 UTC [Leadership Update] [Diality Appoints Peter Donato as Chief Financial Officer](https://www.quantisnow.com/insight/diality-appoints-peter-donato-as-chief-financial-officer-6408721)
- 2025-12-11 11:30 UTC [Market Insight] [Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv](https://www.quantisnow.com/insight/zomedica-announces-collaboration-with-prime-video-as-assisi-loopr-products-6311490)
- 2025-12-04 11:30 UTC [Market Insight] [Zomedica Expands TRUFORMA(R) Diagnostic Menu with Launch of Equine Progesterone Assay](https://www.quantisnow.com/insight/zomedica-expands-truformar-diagnostic-menu-with-launch-of-equine-progesterone-6302723)
- 2025-11-11 11:30 UTC [Market Insight] [Zomedica Announces "Friday at Four" Webinar on November 21st Providing Strategic Overview & Third Quarter 2025 Business Review](https://www.quantisnow.com/insight/zomedica-announces-friday-at-four-webinar-on-november-21st-providing-6271777)
- 2025-11-06 11:30 UTC [Market Insight] [Zomedica Achieves ISO 13485 Certification, Underscoring Strengthened Quality Infrastructure and Commercial Potential](https://www.quantisnow.com/insight/zomedica-achieves-iso-13485-certification-underscoring-strengthened-quality-infrastructure-and-6263820)
- 2025-11-04 21:17 UTC [Market Insight] [Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth](https://www.quantisnow.com/insight/zomedica-announces-third-quarter-2025-financial-results-revenue-up-16-6259467)
- 2025-10-23 10:30 UTC [Market Insight] [Zomedica Announces Launch of the Assisi Loop Lounge(R), Scientifically Backed tPEMF(TM) Therapy for Pets](https://www.quantisnow.com/insight/zomedica-announces-launch-of-the-assisi-loop-lounger-scientifically-backed-6242421)
- 2025-10-14 10:30 UTC [Market Insight] [Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union](https://www.quantisnow.com/insight/zomedica-expands-grovets-distribution-agreement-to-include-zomedicas-diagnostic-and-6231199)
- 2025-10-09 10:30 UTC [Market Insight] [Zomedica to Spotlight VETGuardian(R) Zero Touch(TM) Monitor in October "Fourth Friday at Four" Webinar](https://www.quantisnow.com/insight/zomedica-to-spotlight-vetguardianr-zero-touchtm-monitor-in-october-fourth-6228178)
- 2025-09-23 10:30 UTC [Market Insight] [Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay](https://www.quantisnow.com/insight/zomedica-expands-truformar-diagnostic-platform-with-addition-of-feline-use-6208732)
- 2025-09-18 10:30 UTC [Market Insight] [Zomedica Expands TRUVIEW(R) and TRUFORMA(R) Intellectual Property Portfolio with Four Newly Issued U.S. Patents](https://www.quantisnow.com/insight/zomedica-expands-truviewr-and-truformar-intellectual-property-portfolio-with-four-6204872)
- 2025-09-12 10:30 UTC [Market Insight] [Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUVIEW(R) Digital Cytology Microscope - Transforming Veterinary Imaging](https://www.quantisnow.com/insight/zomedicas-fourth-friday-at-four-webinar-returns-spotlight-on-truviewr-6198732)
- 2025-09-10 10:30 UTC [Market Insight] [Zomedica and UXR Announce Expanded Distribution Agreement in Canada](https://www.quantisnow.com/insight/zomedica-and-uxr-announce-expanded-distribution-agreement-in-canada-6195769)
- 2025-09-03 10:30 UTC [Market Insight] [Zomedica Strengthens UK Market Position with Strategic Distribution Agreement for High-Growth Veterinary Innovation Portfolio](https://www.quantisnow.com/insight/zomedica-strengthens-uk-market-position-with-strategic-distribution-agreement-for-6186856)
- 2025-08-19 10:30 UTC [Market Insight] [Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent Practices](https://www.quantisnow.com/insight/zomedica-and-verticalvet-announce-strategic-partnership-to-deliver-advanced-veterinary-6170839)
- 2025-08-12 10:30 UTC [Market Insight] [Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL(R) Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary Medicine](https://www.quantisnow.com/insight/zomedicas-fourth-friday-at-four-webinar-returns-spotlight-on-the-6159443)
- 2025-08-06 20:12 UTC [Market Insight] [Zomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth](https://www.quantisnow.com/insight/zomedica-announces-second-quarter-2025-financial-results-revenue-up-14-6150592)
- 2025-07-16 10:00 UTC [Market Insight] [Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the Assisi(R) Line - Advancing Drug-Free Healing for Pets](https://www.quantisnow.com/insight/zomedicas-fourth-friday-at-four-webinar-returns-spotlight-on-the-6121236)
- 2025-07-10 10:30 UTC [Market Insight] [Zomedica Announces Strategic PulseVet(R) Shock Wave Partnership with World Equestrian Center – Ocala](https://www.quantisnow.com/insight/zomedica-announces-strategic-pulsevetr-shock-wave-partnership-with-world-equestrian-6116062)
- 2025-06-24 10:30 UTC [Market Insight] [Zomedica Announces Issuance of Additional Patent for its TRUVIEW(R) Microscope](https://www.quantisnow.com/insight/zomedica-announces-issuance-of-additional-patent-for-its-truviewr-microscope-6096466)
- 2025-06-19 10:30 UTC [Market Insight] [Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform(R) - Revolutionizing In-Clinic Diagnostics](https://www.quantisnow.com/insight/zomedicas-fourth-friday-at-four-webinar-returns-spotlight-on-truforma-6092738)
- 2025-05-21 10:30 UTC [Market Insight] [Zomedica Launches Enhanced Equine Insulin Assay for the TRUFORMA(R) Diagnostic Platform Featuring an Extended Range and Automatic Sample Dilution](https://www.quantisnow.com/insight/zomedica-launches-enhanced-equine-insulin-assay-for-the-truformar-diagnostic-6051498)
- 2025-05-19 22:15 UTC [Market Insight] [Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations](https://www.quantisnow.com/insight/zomedica-unveils-exclusive-fourth-friday-at-four-webinar-series-to-6048793)
- 2025-05-13 10:30 UTC [Market Insight] [Zomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave Therapy](https://www.quantisnow.com/insight/zomedica-launches-groundbreaking-equine-asthma-clinical-registry-featuring-pulsevetr-shock-6034482)
- 2025-03-27 13:56 UTC [Insider Buy] [Amendment: Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)](https://www.quantisnow.com/insight/amendment-director-rowe-jeffrey-m-bought-96098-worth-of-shares-5962564)
- 2025-03-20 13:52 UTC [Insider Buy] [Director Williams Rodney James bought $6,900 worth of shares (100,000 units at $0.07), increasing direct ownership by 62% to 261,900 units (SEC Form 4)](https://www.quantisnow.com/insight/director-williams-rodney-james-bought-6900-worth-of-shares-100000-5953824)
- 2025-03-19 15:47 UTC [Insider Buy] [Chief Financial Officer Jordan Scott bought $18,600 worth of shares (300,000 units at $0.06) (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-jordan-scott-bought-18600-worth-of-shares-5951906)
- 2025-03-18 20:52 UTC [Insider Buy] [Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)](https://www.quantisnow.com/insight/director-rowe-jeffrey-m-bought-96098-worth-of-shares-1439005-5950274)
- 2025-03-18 20:48 UTC [Insider Buy] [Director Macleod Christopher Ross bought $8,437 worth of shares (143,000 units at $0.06) (SEC Form 4)](https://www.quantisnow.com/insight/director-macleod-christopher-ross-bought-8437-worth-of-shares-143000-5950245)
- 2025-03-18 20:42 UTC [Insider Buy] [Director Powers Johnny D bought $33,650 worth of shares (500,000 units at $0.07), increasing direct ownership by 21% to 2,925,000 units (SEC Form 4)](https://www.quantisnow.com/insight/director-powers-johnny-d-bought-33650-worth-of-shares-500000-5950197)
- 2025-03-18 20:40 UTC [Insider Buy] [CEO Heaton Larry C Ii bought $29,702 worth of shares (500,000 units at $0.06), increasing direct ownership by 100% to 1,000,000 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-heaton-larry-c-ii-bought-29702-worth-of-shares-5950178)
- 2025-03-18 20:38 UTC [Insider Buy] [COO Blair Anthony K bought $30,000 worth of shares (500,000 units at $0.06), increasing direct ownership by 125% to 900,000 units (SEC Form 4)](https://www.quantisnow.com/insight/coo-blair-anthony-k-bought-30000-worth-of-shares-500000-5950160)
- 2025-03-18 20:36 UTC [Insider Buy] [Sr Vice President of Sales Klass Russell Kevin bought $48,999 worth of shares (699,980 units at $0.07), increasing direct ownership by 28% to 3,200,030 units (SEC Form 4)](https://www.quantisnow.com/insight/sr-vice-president-of-sales-klass-russell-kevin-bought-48999-5950148)
- 2025-03-18 20:24 UTC [Insider Buy] [Director Williams Rodney James bought $6,900 worth of shares (100,000 units at $0.07) (SEC Form 4)](https://www.quantisnow.com/insight/director-williams-rodney-james-bought-6900-worth-of-shares-100000-5949959)
- 2025-03-13 22:59 UTC [SEC Form 8-K] [Zomedica Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/zomedica-corp-filed-sec-form-8-k-results-of-operations-and-5944144)
- 2025-03-13 20:03 UTC [SEC Form 10-K] [SEC Form 10-K filed by Zomedica Corp.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-zomedica-corp-5942949)
- 2025-03-13 16:02 UTC [SEC Form 25-NSE filed by Zomedica Corp.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-zomedica-corp-5942684)
- 2025-03-04 22:30 UTC [Market Insight] [Zomedica Corp. Announces Transition to OTCQB Venture Market](https://www.quantisnow.com/insight/zomedica-corp-announces-transition-to-otcqb-venture-market-5925225)
- 2025-02-26 11:30 UTC [Market Insight] [Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET](https://www.quantisnow.com/insight/zomedica-to-report-fourth-quarter-and-full-year-2024-financial-5910049)
- 2025-02-24 21:30 UTC [SEC Form 4] [SEC Form 4 filed by Sr Vice President of Sales Klass Russell Kevin](https://www.quantisnow.com/insight/sec-form-4-filed-by-sr-vice-president-of-sales-5905652)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ZOM
- Earnings history: https://www.quantisnow.com/earnings/ZOM
- Dividend history: https://www.quantisnow.com/dividends/ZOM
- Insider transactions: https://www.quantisnow.com/insiders/ZOM
- Options chain: https://www.quantisnow.com/options/ZOM
- SEC 8-K filings only: https://www.quantisnow.com/company/ZOM/8-k
- RSS and alerts for ZOM: https://www.quantisnow.com/docs/rss-feeds.md
